Asymchem (06821) Rises Over 3% as Q1-Q3 Net Profit Grows 12.66% YoY, Emerging Businesses Poised as Core Growth Driver

Stock News11-07

Asymchem (06821) surged over 3%, reaching HK$85.8 by the time of writing, with a trading volume of HK$13.68 million. The company recently announced its financial results for the first three quarters of 2025, reporting revenue of RMB4.63 billion, up 11.82% year-on-year, and net profit attributable to shareholders of RMB800 million, a 12.66% increase YoY. Basic earnings per share stood at RMB2.18.

The company noted that based on its order backlog for the second half of the year, Q4 deliveries are expected to significantly surpass Q3 levels, projecting full-year revenue growth of 13%-15%. Guosen Securities highlighted that while Asymchem's core small-molecule CDMO business saw flat YoY revenue growth in Q1-Q3 2025 with a gross margin of 47.0% (down 1.9 percentage points), its emerging businesses demonstrated robust expansion.

Emerging business revenue jumped 71.9% YoY, with gross margin improving by 10.6 percentage points to 30.6%. Notably, chemical macromolecule business revenue more than doubled. The company continues to expand its market presence in peptide, oligonucleotide, and ADC sectors, securing double-digit growth in new orders. Coupled with capacity expansion, these emerging businesses are positioned to become the primary growth engine.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101286379?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 10:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101286379","market":"hk","top_or_hot":-1,"title":"Asymchem (06821) Rises Over 3% as Q1-Q3 Net Profit Grows 12.66% YoY, Emerging Businesses Poised as Core Growth Driver","media":"Stock News","content":"<p>Asymchem (06821) surged over 3%, reaching HK$85.8 by the time of writing, with a trading volume of HK$13.68 million. The company recently announced its financial results for the first three quarters of 2025, reporting revenue of RMB4.63 billion, up 11.82% year-on-year, and net profit attributable to shareholders of RMB800 million, a 12.66% increase YoY. Basic earnings per share stood at RMB2.18.</p>\n<p>The company noted that based on its order backlog for the second half of the year, Q4 deliveries are expected to significantly surpass Q3 levels, projecting full-year revenue growth of 13%-15%. Guosen Securities highlighted that while Asymchem's core small-molecule CDMO business saw flat YoY revenue growth in Q1-Q3 2025 with a gross margin of 47.0% (down 1.9 percentage points), its emerging businesses demonstrated robust expansion.</p>\n<p>Emerging business revenue jumped 71.9% YoY, with gross margin improving by 10.6 percentage points to 30.6%. Notably, chemical macromolecule business revenue more than doubled. The company continues to expand its market presence in peptide, oligonucleotide, and ADC sectors, securing double-digit growth in new orders. Coupled with capacity expansion, these emerging businesses are positioned to become the primary growth engine.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Asymchem (06821) Rises Over 3% as Q1-Q3 Net Profit Grows 12.66% YoY, Emerging Businesses Poised as Core Growth Driver</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAsymchem (06821) Rises Over 3% as Q1-Q3 Net Profit Grows 12.66% YoY, Emerging Businesses Poised as Core Growth Driver\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-07 10:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Asymchem (06821) surged over 3%, reaching HK$85.8 by the time of writing, with a trading volume of HK$13.68 million. The company recently announced its financial results for the first three quarters of 2025, reporting revenue of RMB4.63 billion, up 11.82% year-on-year, and net profit attributable to shareholders of RMB800 million, a 12.66% increase YoY. Basic earnings per share stood at RMB2.18.</p>\n<p>The company noted that based on its order backlog for the second half of the year, Q4 deliveries are expected to significantly surpass Q3 levels, projecting full-year revenue growth of 13%-15%. Guosen Securities highlighted that while Asymchem's core small-molecule CDMO business saw flat YoY revenue growth in Q1-Q3 2025 with a gross margin of 47.0% (down 1.9 percentage points), its emerging businesses demonstrated robust expansion.</p>\n<p>Emerging business revenue jumped 71.9% YoY, with gross margin improving by 10.6 percentage points to 30.6%. Notably, chemical macromolecule business revenue more than doubled. The company continues to expand its market presence in peptide, oligonucleotide, and ADC sectors, securing double-digit growth in new orders. Coupled with capacity expansion, these emerging businesses are positioned to become the primary growth engine.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1101286379","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101286379","pubTimestamp":1762483697,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Asymchem (06821) surged over 3%, reaching HK$85.8 by the time of writing, with a trading volume of HK$13.68 million. The company recently announced its financial results for the first three quarters...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0239":"医药制造","BK0132":"高送转概念","06821":"凯莱英","BK1191":"制药","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","002821":"凯莱英"},"translate_title":"凯莱英(06821)涨超3%Q1-Q3净利润同比增长12.66%新兴业务有望成为核心增长动力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002821":1,"06821":1},"content_text":"Asymchem (06821) surged over 3%, reaching HK$85.8 by the time of writing, with a trading volume of HK$13.68 million. The company recently announced its financial results for the first three quarters of 2025, reporting revenue of RMB4.63 billion, up 11.82% year-on-year, and net profit attributable to shareholders of RMB800 million, a 12.66% increase YoY. Basic earnings per share stood at RMB2.18.\nThe company noted that based on its order backlog for the second half of the year, Q4 deliveries are expected to significantly surpass Q3 levels, projecting full-year revenue growth of 13%-15%. Guosen Securities highlighted that while Asymchem's core small-molecule CDMO business saw flat YoY revenue growth in Q1-Q3 2025 with a gross margin of 47.0% (down 1.9 percentage points), its emerging businesses demonstrated robust expansion.\nEmerging business revenue jumped 71.9% YoY, with gross margin improving by 10.6 percentage points to 30.6%. Notably, chemical macromolecule business revenue more than doubled. The company continues to expand its market presence in peptide, oligonucleotide, and ADC sectors, securing double-digit growth in new orders. Coupled with capacity expansion, these emerging businesses are positioned to become the primary growth engine.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101286379","isCrawlerRequest":true}